VADC45 / PureTech, Vor Biopharma - LARVOL DELTA

Vor Bio Announces $55.6 Million Private Placement (GlobeNewswire) - "Vor Bio...today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the PIPE) that is expected to result in gross proceeds of approximately $55.6 million, before deducting placement agent fees and other expenses...Vor Bio expects to use net proceeds from the PIPE to fund clinical and preclinical development of its pipeline candidates and for general corporate purposes....Vor Bio expects to announce updated clinical data from the Phase 1/2 VBP301 trial of VCAR33^ALLO in the first half of 2025 and updated clinical data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025."

Financing • P1/2 data • Acute Myelogenous Leukemia • Myelodysplastic Syndrome

Vor Bio announced today, a new preclinical asset, VADC45, which has a number of potential opportunities in oncology, gene therapy, and autoimmune disorders. (Businesswire) - "VADC45 is an ADC that targets the CD45 protein. CD45 is a well-validated target for a wide variety of blood cancers with clinical proof of concept. The linker-payload used in VADC45 is also clinically validated. VADC45 has the potential to treat a number of diseases, including treatment of hematologic malignancies, as a targeted conditioning agent for gene therapies such as for sickle cell disease, holistic immune reset for autoimmune disorders, and for Vor Bio’s approach of combining this asset with epitope modification of CD45 to shield healthy stem cells. Vor Bio already has robust preclinical data for VADC45 and is progressing IND-enabling studies to enable future Phase 1 studies."

Preclinical • Genetic Disorders • Hematological Malignancies • Immunology • Oncology • Sickle Cell Disease